ǂa ǂretrospective analysis from an early access program
Hannah Fabikan (Avtor), Aurélie Swalduz (Avtor), Anders Vikström (Avtor), Dagmar Krenbek (Avtor), Michael Schumacher (Avtor), Elizabeth Dudnik (Avtor), Michael Studnicka (Avtor), Ronny Öhman (Avtor), Robert Wurm (Avtor), Tanja Čufer (Avtor), Katja Mohorčič (Avtor), Maximilian J Hochmair (Avtor), Oliver Illini (Avtor)

Povzetek

Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal–epithelial transition (MET) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor, which showed promising efficacy in this patient population in early trials. Methods: We performed a retrospective, international, multicenter efficacy and safety analysis in patients with NSCLC treated with capmatinib in an early access program between March 2019 and December 2021. Results: Data from 81 patients with advanced MET exon 14 mutated NSCLC treated with capmatinib in first- or later-line therapy were analyzed. Median age was 77years (range, 48–91), 56% were women, 86% had stage IV disease, and 27% had brain metastases. For all patients, the objective response rate (ORR) to capmatinib was 58% (95% CI, 47–69), whereas it was 68% (95% CI, 50–82) in treatment-naïve and 50% (95% CI, 35–65) in pretreated patients. The median progression-free survival was 9.5months (95% CI, 4.7–14.3), whereas it was 10.6months (95% CI, 5.5–15.7) in first-line and 9.1months (95% CI, 3.1–15.1) in pretreated patients. After a median follow-up of 11.0months, the median overall survival was 18.2 months (95% CI, 13.2–23.1). In patients with measurable brain metastases (n=11), the intracranial ORR was 46% (95% CI, 17–77). Capmatinib showed a manageable safety profile. Grade⩾3 treatment-related adverse events included peripheral edema (13%), elevated creatinine (4%), and elevated liver enzymes (3%). Conclusion: In patients with MET exon 14 skipping mutation, capmatinib showed durable systemic and intracranial efficacy and a manageable safety profile. This analysis confirms previously reported phase II data in a real-world setting.

Ključne besede

podatki iz resničnega življenja;capmatinib;tarčna terapija;real-world data;targeted therapy;

Podatki

Jezik: Angleški jezik
Leto izida:
Tipologija: 1.01 - Izvirni znanstveni članek
Založnik: Sage Publications
UDK: 616-006
COBISS: 112187139 Povezava se bo odprla v novem oknu
ISSN: 1758-8359
Št. ogledov: 76
Št. prenosov: 76
Ocena: 0 (0 glasov)
Metapodatki: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Ostali podatki

Sekundarne ključne besede: Carcinoma, non-small cell lung;Drug therapy;Genetics;Molecular targeted therapy;Nedrobnocelični karcinom pljuč;Terapija z zdravili;Genetika;Molekularna tarčna terapija;
Komentar vira: Nasl. z nasl. zaslona; Soavtorici iz Slovenije: Katja Mohorčič, Tanja Čufer; Opis vira z dne 20. 6. 2022;
Strani: str. 1-22
Zvezek: ǂVol. ǂ14
Čas izdaje: Jan./Dec. 2022
DOI: 10.1177/17588359221103206
ID: 15730078